Immunity against SARS-CoV-2 in Dutch populatio
Recruiting
- Conditions
- <p>COVID-19, SARS-CoV-2</p>
- Registration Number
- NL-OMON21435
- Lead Sponsor
- ational Institute for Public Health and the Environment (RIVM)
- Brief Summary
https://pubmed.ncbi.nlm.nih.gov/33632374/ https://pubmed.ncbi.nlm.nih.gov/33624751/ https://pubmed.ncbi.nlm.nih.gov/33249407/ https://pubmed.ncbi.nlm.nih.gov/33772265/ https://pubmed.ncbi.nlm.nih.gov/34114187/
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 14000
Inclusion Criteria
Subject previously participated in the PIENTER 3 study (2016/17) and had indicated that they could be approached for a follow-up study, or Subjects from a random age-stratified sample from the Netherlands
Exclusion Criteria
There are no exclusion criteria.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum</p>
- Secondary Outcome Measures
Name Time Method <p>To assess the quantity and quality (i.e. antibody functionality and avidity) of the antibodies raised against SARS-CoV-2 in a representative part of the Dutch population, and to identify subgroups (including risk groups) with different levels of immunity against COVID-19. To assess the development of immunity during and after the first pandemic wave and the period thereafter. To assess the existence of cross-reactive antibodies against established coronavirus infections in the past. To determine the duration of immunity and the cross-immunity to new variants of SARS-CoV-2 induced by infection and/or vaccination. To study the impact of COVID-19 control measures on immunity to, and infection with, respiratory pathogens that are of epidemiological and clinical concern once they resurge in the Dutch population.</p>